Genetic instability of tumor cells often leads to the occurrence of a large number of
mutations, and expression of non-synonymous mutations can produce tumor-specific …

Accumulating evidence indicates that the innate and adaptive immune systems make a
crucial contribution to the antitumour effects of conventional chemotherapy-based and …

In the past decade, basic studies in animal models have begun to elucidate the
physiological barriers which impede a successful antitumor immune response. These …

Immunotherapy studies in patients with melanoma have reported success in the expansion
of tumour-specific effector T cells in vivo, but even in the presence of substantial numbers of …

The accumulation of regulatory T cells (Tregs) at high density in various human carcinomas
is generally associated with a poor prognosis, as expected from their capacity to inhibit …

Drug repositioning refers to the utilization of a known compound in a novel indication
underscoring a new mode of action that predicts innovative therapeutic options. Since 1959 …

PURPOSE: Allogeneic granulocyte-macrophage colony-stimulating factor (GM-CSF)–
secreting tumor vaccines can cure established tumors in the mouse, but their efficacy …

Pancreatic cancer remains one of the most lethal cancers with few treatment options.
Immune-based strategies to treat pancreatic cancer, such as immune checkpoint inhibitors …

Tumor-specific immune tolerance limits the effectiveness of cancer vaccines. In addition,
tumor vaccines alone have a limited potential for the treatment of measurable tumor …

Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for several
malignancies. While the use of single-agent or combined ICIs has achieved acceptable …